F. Huang, F. Feng
Mar 21, 2019
Citations
0
Influential Citations
34
Citations
Journal
Cell
Abstract
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.